NORVIR (Abbvie Pty Ltd)
Product name
NORVIR
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
140 (255 working days)
Active ingredients
Ritonavir
Registration type
EOI
Indication
Ritonavir is indicated as a pharmacokinetic enhancer of co-administered protease inhibitors as part of antiretroviral combination therapy for the treatment of adults and children aged 12 years and older with HIV-1 infection.